Clinical improvement of diabetes mellitus type 1 by b-D-mannuronic acid (M2000) in a breast cancer patient — as a case report
, 23, 3, 2, 1
Abstract
A 56 years old female with breast cancer (BC) and poor controlled diabetes mellitus type 1 (DM1) which has registered in a clinical trial for assessment of therapeutic efficacy of b-D-mannuronic acid (M2000) on pre-surgical BC patients is described in this case report. After receiving M2000, the patient was followed for 9 weeks. During this period, cancer mass details, fasting blood glucose (FBG) levels, 2-hour post-prandial blood glucose (2HPP), blood uric acid (BUA) level and urine analysis (UA) were continuously controlled. After 9 weeks of treatment with M2000, her FBG, BUA and UA decreased significantly. This finding was exactly in accordance with our published experimental data about the anti-diabetic effect of M2000 in an animal model. Therefore, it might be concluded that M2000 is probably able to improve DM1 by reducing FBG level, BUA level, glycosuria, ketonuria and proteinuria.
Keywords: b-D-mannuronic acidM2000breast cancerdiabetes mellitusNSAID
References
- Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(49): e5602.
- Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes. 2014; 5(3): 372–380.
- Fattahi MJ, Abdollahi M, Agha Mohammadi A, et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol. 2015; 37(6): 535–540.
- Mirshafiey A, Taeb M, Mortazavi-Jahromi SS, et al. Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacol Rep. 2017; 69(5): 1067–1072.
- Mirshafiey A, Cuzzocrea S, Rehm BHA, et al. M2000: a revolution in pharmacology. Med Sci Monit. 2005; 11(8): PI53–PI63.
- Hosseini F, Hassannia H, Mahdian-Shakib A, et al. Targeting of crosstalk between tumor and tumor microenvironment by β-D mannuronic acid (M2000) in murine breast cancer model. Cancer Med. 2017; 6(3): 640–650.
- Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012; 23(6): 967–981.
- M Farahani M, Motevaseli E, Maghsood F, et al. Anti-inflammatory property of β-D-Mannuronic acid (M2000) on expression and activity of matrix metalloproteinase-2 and -9 through CD147 molecule in phorbol myristate acetate-differentiated THP-1 cells. Iran J Allergy Asthma Immunol. 2017; 16(5): 443–451.
- Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH, et al. Anti-diabetic effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model. Arch Physiol Biochem. 2018 [Epub ahead of print]: 1–6.
- Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH, et al. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model. Immunopharmacol Immunotoxicol. 2018; 40(4): 284–289.